HIGH-RISK HUMAN PAPILLOMAVIRUS (hrHPV) INFECTION AND CARCINOGENESIS IN THE CERVIX UTERI
=======================================================================================

The human papillomaviruses (HPVs) consist of a heterogeneous group of capsid-enclosed double-stranded DNA viruses from the *Papillomaviridae* family that have a histological tropism for squamous epithelium \[[@B1]\]. The HPV genome is composed of the following 3 major regions: the early (E) region encoding nonstructural proteins, the late (L) region encoding the 2 capsid proteins, and the noncoding long control region that regulates viral replication and gene expression \[[@B2][@B3]\]. E5, E6, and E7 directly promote cellular transformation and alter pathways related to the immune response. The most notable activity of E6 is degradation of the tumor suppressor protein p53 via the proteasome pathway, and the E7 protein binds to the hypophosphorylated form of retinoblastoma protein and promotes its degradation via the ubiquitin-proteasome pathway.

Recently, more than 170 HPV types have been isolated and characterized \[[@B4]\]. Among them, the International Agency for Research on Cancer Monographs classified these hrHPV (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, and HPV59) as group 1 carcinogens for cervical cancer \[[@B5][@B6][@B7]\]. HPV16 and HPV18 are the most common carcinogenic types within this group and are responsible for approximately 50% and 20% of cervical cancer, respectively \[[@B8]\]. The major steps in cervical carcinogenesis are HPV infection in cervical basal cells, progression to a precancerous lesion, and cancer invasion ([Fig. 1](#F1){ref-type="fig"}).
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SCREENING STRATEGIES FOR HPV-ASSOCIATED CERVICAL DISEASE
========================================================

Cervical cancer is the 4th most frequent cancer and the 4th leading cause of cancer death in women, with an estimated 570,000 cases and 311,000 deaths in 2018 worldwide \[[@B9]\]. In Korean women, cervical cancer is the 7th most common malignancy, and the incidence rate is still higher than that in other developed countries \[[@B10]\]. Based on cytology-based screening (Papanicolaou smear or liquid-based cytology) for cervical cancer, the incidence and associated mortality of cervical cancer have continued to decrease worldwide \[[@B11][@B12][@B13]\]. Since the introduction of the national cervical cancer screening program in 1999 in Korea, the incidence rate of cervical cancer has also steadily decreased from 16.3/100,000 to 9.1/100,000 in 2015 \[[@B14]\]. In 2015, the National Cervical Cancer Screening Guideline Development Committee, which is composed of experts from the Korean Society of Gynecologic Oncology, the Korean Society for Cytopathology, the Korean Society for Preventive Medicine, and the Korean Academy of Family Medicine, recommended a cytology-based screening for cervical cancer every 3 years in women older than 20 years old \[[@B15]\]. However, this cytology-based screening has a sensitivity of 51%--53% in detecting high-grade cervical intraepithelial neoplasia (CIN) \[[@B16][@B17][@B18]\].

Cytology depends on the morphological analysis of cervical exfoliated cells. Compared to cytology, HPV testing does not depend on morphological analysis and is commonly based on the detection of HPV DNA or mRNA. With the understanding of the causal relationship between hrHPV infection and cervical carcinogenesis, the Atypical Squamous Cells of Undetermined Significance/Low Grade Squamous Intraepithelial Lesion Triage Study showed that reflex hrHPV testing of the cytological category of "atypical squamous cells of undetermined significance" (ASCUS) resulting in a triage of colposcopy can be a feasible alternative to cytology alone \[[@B19]\]. The HPV triage test has been considered the preferred management for women with ASCUS on cytology since the early 2000s \[[@B20]\]. In 2003, the US Food and Drug Administration (US-FDA) approved the use of HPV testing as a reflex test in women over 21 years with ASCUS and as an adjunctive test in women over 30 years. Currently, the US-FDA approves the use of Cobas^®^ HPV (Roche Diagnostics, Basel, Switzerland) and Onclarity^®^ HPV (BD, Franklin Lakes, NJ, USA) as primary screening tests for cervical cancer. In Korea, Cobas^®^ HPV has been approved as a primary screening test for cervical cancer. However, in 2015, the National Cervical Cancer Screening Guideline Development Committee stated that the existing evidence regarding the advantages and disadvantages of primary HPV testing is very low and the level of evidence regarding the effects of HPV/cytology co-testing is moderate \[[@B15]\].

SCIENTIFIC EVIDENCE OF hrHPV TESTING AS A PRIMARY SCREENING
===========================================================

The first randomized controlled trial (RCT) found that HPV screening had a higher sensitivity (95%) in detecting high-grade CIN than cytology (55%) \[[@B21]\]. RCTs discussed in this study are summarized in [Table 1](#T1){ref-type="table"}. Four European RCTs (Swedescreen, Population-Based Screening Study Amsterdam, A Randomized Trial in Screening to Improve Cytology \[ARTISTIC\], and New Technologies for Cervical Cancer Screening \[NTCC\]) showed that earlier HPV-based screening in patients detects persistent high-grade CIN with higher sensitivity than cytology, thus the incidence of high-grade CIN was lower after HPV screening than after cytology \[[@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29]\]. Furthermore, a pooled analysis of these European RCTs found that HPV screening provides 60%--70% greater protection against cervical cancers than cytology \[[@B30]\]. In the USA, the Addressing THE Need for Advanced HPV Diagnostics (ATHENA) trial showed higher sensitivity in detecting CIN3+ (CIN3 and cervical cancer) in the HPV primary strategy group than in the cytology strategy group (76.1% vs. 47.8%) in 2015 \[[@B31]\]. Women in the HPV primary strategy group underwent colposcopy if they were found positive for HPV16 or HPV18 (or underwent reflex cytology if other types of HPV were positive) in the ATHENA trial.

###### Results of randomized controlled trials of high-risk human papillomavirus screening, with or without co-testing
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  Study                                     No. of participants     Ages included (yr)                                          Screening interval (yr)   Arms                    Criteria for immediate colposcopy                           Absolute detection (%)   Colposcopy referral rate (%)   Follow-up period (maximum, yr)   
  ----------------------------------------- ----------------------- ----------------------------------------------------------- ------------------------- ----------------------- ----------------------------------------------------------- ------------------------ ------------------------------ -------------------------------- -----------
  Swedescreen \[[@B22]\]                    12,527                  32--38                                                      3                         Conventional cytology   ASCUS+                                                      55/6,270 (0.9)           NR                             NR                               Mean: 4.1
  hrHPV with conventional cytology          ASCUS+                  72/6,257 (1.2)                                              NR                        NR                                                                                                                                                                           
  POBASCAM \[[@B23][@B24][@B25]\]           44,938                  29--61                                                      5                         Conventional cytology   HSIL+                                                       150/20,106 (0.7)         6/20,109 (0.03)                NR                               9.0
  hrHPV with conventional cytology          HSIL+                   171/19,999 (0.9)                                            12/19,999 (0.06)          NR                                                                                                                                                                           
  ARTISTIC \[[@B26][@B27]\]                 24,510                  20--64                                                      3                         LBC                     HSIL+                                                       81/6,124 (1.3)           4/6,124 (0.07)                 320/6,124 (5.2)                  4.5
  hrHPV with LBC                            HSIL+                   233/18,386 (1.3)                                            5/18,386 (0.03)           1,247/18,386 (6.8)                                                                                                                                                           
  NTCC \[[@B28][@B29]\]                     49,196                  25--60                                                      3                         Conventional cytology   ASCUS+ or LSIL+                                             33/24,535 (0.1)          NR                             679/25,435 (2.8)                 7.0
  hrHPV                                     hrHPV+                  97/24,661 (0.4)                                             NR                        1,936/24,661 (7.9)                                                                                                                                                           
  HPV FOCAL \[[@B44][@B45][@B46][@B47]\]    19,000                  25--65                                                      4                         LBC with hrHPV triage   ASCUS+ and hrHPV+ (or, for cytology only, ASC-H or LSIL+)   41/9,408 (0.4)           NR                             290/9,408 (3.1)                  4.0
  hrHPV with LBC triage                     hrHPV+ and ASCUS+       67/9,540 (0.7)                                              NR                        544/9,540 (5.7)                                                                                                                                                              
  FINNISH \[[@B48]\]                        203,425                 25--65                                                      5                         Conventional cytology   LSIL+                                                       118/65,784 (0.2)         9/65,784 (0.01)                755/65,784 (1.1)                 5.0
  hrHPV with conventional cytology triage   hrHPV+ and LSIL+        195/66,410 (0.3)                                            17/66,410 (0.03)          796/66,410 (1.2)                                                                                                                                                             
  Compass \[[@B49]\]                        4,995                   25--64                                                      2.5                       LBC                     ASC-H+/HSIL+                                                1/995 (0.1)              0/995 (0)                      27/995 (2.7)                     2.5
  5                                         hrHPV with LBC triage   HPV16/18+, other hrHPV+ with LSIL or ASC-H+ or p16/Ki-67+   30/4,000 (0.8)            0/4,000 (0)             154/4,000 (3.8)                                             5.0                                                                                      
  ATHENA \[[@B31]\]                         40,901                  ≥25                                                         3                         Cytology                ASCUS+ or hrHPV+                                            179/45,156 (0.4)         NR                             1,934/45,156 (4.3)               3.0
  HPV primary                               294/52,651 (0.6)        NR                                                          3,769/52,651 (7.2)                                                                                                                                                                                     
  Hybrid strategy^\*^                       240/82,994 (0.3)        NR                                                          3,097/82,994 (3.7)                                                                                                                                                                                     

ARTISTIC, A Randomized Trial in Screening to Improve Cytology; ASCUS, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; ATHENA, Addressing THE Need for Advanced HPV Diagnostics; CIN, cervical intraepithelial neoplasia; hrHPV, high-risk human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; HPV, human papillomavirus; HPV FOCAL, Human Papillomavirus for Cervical Cancer Screening; LBC, liquid-based cytology; LSIL, low-grade squamous intraepithelial lesion; NR, not reported; NTCC, New Technologies for Cervical Cancer Screening; POBASCAM, Population-Based Screening Study Amsterdam.

^\*^A hybrid strategy uses the cytology strategy for women 25--29 years old and co-testing with both cytology and HPV (pooled 14 genotypes) in women ≥30 years.

Three-year risks for CIN3+ following a negative result in hrHPV screening or HPV/cytology co-testing were significantly lower than those of cytology alone in the ATHENA trial and Gage\'s study \[[@B31][@B32]\]. A US Preventive Services Task Force (US-PSTF) systematic review also found that hrHPV screening detected CIN3+ with a higher rate than cytology. However, HPV/cytology co-testing did not increase the detection rate of CIN3+ \[[@B33]\]. Instead, hrHPV screening and HPV/cytology co-testing both increased the number of diagnostic colposcopies \[[@B33]\].

Randomized trials for primary HPV screening have not yet been published in Korea. In 2016, Choi et al. \[[@B34]\] retrospectively compared the clinical performance of primary HPV screening, HPV/cytology co-testing, and cytology alone using 1,000 cervical samples. The sensitivity was calculated using CIN2+ with colposcopy biopsy as the gold standard, and the sensitivities of primary HPV screening, HPV/cytology co-testing, and cytology alone were 71.7%, 72.5%, and 63.8%, respectively.

OTHER CURRENT RECOMMENDATIONS: STARTING AGE AND SCREENING INTERVAL
==================================================================

Guidelines for cervical cancer screening in several countries are summarized in [Table 2](#T2){ref-type="table"}. The National Institute for Public Health and the Environment in the Netherlands revealed that the HPV screening for women aged 30--60 years every 5 years was the primary screening method in their national cervical cancer screening program \[[@B35]\]. Moreover, in Australia, the Papanicolaou test performed biannually for women aged 18--69 years has been replaced by HPV screening performed once in 5 years for women aged 25--74 years \[[@B36]\]. However, the ideal starting age and screening interval of primary HPV screening are still under investigation. The Society for Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology issued interim guidelines recommending primary HPV screening as an acceptable approach in women 25--65 years old based on the ATHENA trial \[[@B37]\]. Although disease detection increases, there are concerns about potential disadvantages, such as unwarranted diagnostic colposcopies, of primary hrHPV screening before the age of 25 years. Several diseases detected in this age group can be safely treated up until the age of 30 years \[[@B38][@B39][@B40]\]. Therefore, general guidelines have recommended less aggressive management for cervical abnormalities in these age groups, and most RCTs enrolled their study populations based on this evidence \[[@B41]\].

###### Guidelines for cervical cancer screening in different countries
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  Country                                  Screening ages (yr)                  Primary screening test and interval                                            Use of hrHPV screening                                                          
  ---------------------------------------- ------------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------------------------------------- ---------------------------------
  Australia \[[@B36]\]                     25--69                               hrHPV screening with partial HPV genotyping and reflex LBC triage every 5 yr   \-                                                                              
  Canada \[[@B50][@B51]\]                  25--69                               Cytology every 3 yr                                                            With regional variation and rollout of primary HPV screening in pilot studies   
  England \[[@B52][@B53]\]                 25--49                               hrHPV screening every 3 yr                                                     \-                                                                              
  50--64                                   hrHPV screening every 5 yr           \-                                                                                                                                                             
  Germany \[[@B52][@B54]\]                 ≥20                                  Cytology annually                                                              HPV primary testing in implementation, HPV triage testing \[[@B55]\]            
  Netherlands \[[@B35]\]                   30--64                               hrHPV screening every 5 yr                                                     \-                                                                              
  Singapore \[[@B56]\]                     25--29                               Cytology every 3 yr                                                            \-                                                                              
  30--69                                   hrHPV screening every 5 yr           \-                                                                                                                                                             
  Sweden \[[@B52]\]                        23--50                               hrHPV screening every 3 yr                                                     \-                                                                              
  51--60                                   hrHPV screening every 5 yr           \-                                                                                                                                                             
  USA                                                                                                                                                                                                                                          
                                           ACS/ASCCP/ASCP (2012) \[[@B57]\]     21--29                                                                         Cytology every 3 yr                                                             \-
  30--65                                   Co-testing every 5 yr (preferred)    \-                                                                                                                                                             
  Cytology every 3 yr                                                                                                                                                                                                                          
                                           Interim guidance (2015) \[[@B58]\]   ≥25                                                                            \-                                                                              hrHPV screening with genotyping
                                           US-PSTF (2018) \[[@B42]\]            21--29                                                                         Cytology every 3 yr                                                             \-
  30--65                                   Cytology every 3 yr (preferred)      \-                                                                                                                                                             
  hrHPV screening every 5 yr (preferred)                                                                                                                                                                                                       
  Co-testing every 5 yr                                                                                                                                                                                                                        

ACS, American Cancer Society; ASCP, American Society for Clinical Pathology; ASCCP, American Society for Colposcopy and Cervical Pathology; hrHPV, high-risk human papillomavirus; HPV, human papillomavirus; LBC, liquid-based cytology; US-PSTF, US Preventive Services Task Force.

Gage et al. \[[@B32]\] compared the 3- and 5-year risks of cervical cancer in women with negative hrHPV screening and negative HPV/cytology co-testing. The 3-year risk in women with a hrHPV-negative result was lower than the 5-year risk in women with a cytology-negative/hrHPV-negative co-testing result (0.011% vs. 0.014%, p=0.21). These results show that hrHPV screening with a 3-year interval is at least as effective as a 5-year interval co-testing. The guidelines issued in September 2018 by the US-PSTF confirmed a similar protocol, recommending HPV screening or HPV/cytology co-testing every 5 years for women aged 30--65 years \[[@B42]\]. In the US-PSTF systematic review, a microsimulation model suggested similar life-years achieved by HPV screening with 3- and 5-year intervals, but in a 3-year interval, several tests and procedures were required \[[@B43]\]. A pooled analysis of European RCTs also showed that 5-year intervals for HPV screening were safer than 3-year intervals for cytology \[[@B30]\]. However, 3 (Swedescreen, ARTISTIC, NTCC) of the 4 European RCTs utilized 3-year screening intervals and follow-up data based on the ATHENA trial \[[@B22][@B27][@B29][@B31]\].

CONCLUSION
==========

For almost 2 decades, scientific evidence from large-scale epidemiological studies has established the diagnostic and preventive value of primary hrHPV screening for high-grade CIN and cervical cancer. However, there are still several challenges in the introduction of hrHPV screening in Korea. First, direct cost-effectiveness comparisons among primary hrHPV screening, cytology, and HPV/cytology co-testing are required. Comparative effectiveness studies that consider the starting age, screening interval, and follow-up visits for primary hrHPV screening are also necessary. These studies may be time-consuming and will likely require significant effort. Nevertheless, the scientific evidence for hrHPV screening should be strongly considered, and we should consider integrating hrHPV screening with published screening and treatment guidelines and comprehensively discuss this new strategy to healthcare providers and patients.
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